Jeil Pharmaceutical Co.,Ltd (KRX:271980)
South Korea
· Delayed Price · Currency is KRW 14,260
+250 (1.78%)
Apr 29, 2026, 3:30 PM KST
KRX:271980 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Operating Revenue | 567,244 | 704,542 | 726,394 | 722,230 | 700,693 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | -0 | -0 | Upgrade
|
| Revenue | 567,244 | 704,542 | 726,394 | 722,230 | 700,693 | Upgrade
|
| Revenue Growth (YoY) | -19.49% | -3.01% | 0.58% | 3.07% | 1.35% | Upgrade
|
| Cost of Revenue | 354,341 | 527,047 | 542,138 | 565,432 | 545,122 | Upgrade
|
| Gross Profit | 212,904 | 177,495 | 184,256 | 156,798 | 155,571 | Upgrade
|
| Selling, General & Admin | 145,422 | 138,562 | 131,225 | 128,897 | 125,363 | Upgrade
|
| Research & Development | 44,971 | 38,772 | 45,727 | 41,147 | 38,974 | Upgrade
|
| Other Operating Expenses | 832.59 | 19,750 | 511.83 | 456.31 | -11.35 | Upgrade
|
| Operating Expenses | 191,908 | 196,044 | 175,368 | 170,130 | 165,951 | Upgrade
|
| Operating Income | 20,995 | -18,550 | 8,888 | -13,332 | -10,380 | Upgrade
|
| Interest Expense | -4,395 | -5,057 | -6,033 | -3,009 | -1,967 | Upgrade
|
| Interest & Investment Income | 1,565 | 1,183 | 1,031 | 115.6 | 75.84 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | 2,516 | Upgrade
|
| Currency Exchange Gain (Loss) | 32.49 | 2,162 | -225.05 | 99.93 | 90.65 | Upgrade
|
| Other Non Operating Income (Expenses) | 155.98 | -7,310 | -2,359 | 946.33 | -3,311 | Upgrade
|
| EBT Excluding Unusual Items | 18,354 | -27,571 | 1,302 | -15,180 | -12,975 | Upgrade
|
| Gain (Loss) on Sale of Investments | 16,585 | 1,136 | 614.01 | 1,923 | -506.61 | Upgrade
|
| Gain (Loss) on Sale of Assets | 12.08 | 7.97 | 0.53 | 9.99 | 30 | Upgrade
|
| Asset Writedown | - | -531.3 | - | - | -382 | Upgrade
|
| Pretax Income | 34,950 | -26,959 | 1,916 | -13,247 | -13,834 | Upgrade
|
| Income Tax Expense | 2,949 | 3,184 | -3,284 | 1,762 | 1,152 | Upgrade
|
| Earnings From Continuing Operations | 32,001 | -30,143 | 5,201 | -15,009 | -14,986 | Upgrade
|
| Minority Interest in Earnings | -8,617 | 174.67 | -195.83 | 1,918 | 2,512 | Upgrade
|
| Net Income | 23,384 | -29,968 | 5,005 | -13,091 | -12,473 | Upgrade
|
| Net Income to Common | 23,384 | -29,968 | 5,005 | -13,091 | -12,473 | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Change (YoY) | 0.01% | -0.02% | -0.02% | -0.23% | -0.04% | Upgrade
|
| EPS (Basic) | 1605.00 | -2057.00 | 343.46 | -898.19 | -853.81 | Upgrade
|
| EPS (Diluted) | 1605.00 | -2057.00 | 343.46 | -898.19 | -853.81 | Upgrade
|
| Free Cash Flow | -13,722 | -1,065 | -11,077 | -26,232 | 13,756 | Upgrade
|
| Free Cash Flow Per Share | -941.83 | -73.10 | -760.21 | -1799.81 | 941.63 | Upgrade
|
| Dividend Per Share | - | - | 50.000 | 50.000 | - | Upgrade
|
| Gross Margin | 37.53% | 25.19% | 25.37% | 21.71% | 22.20% | Upgrade
|
| Operating Margin | 3.70% | -2.63% | 1.22% | -1.85% | -1.48% | Upgrade
|
| Profit Margin | 4.12% | -4.25% | 0.69% | -1.81% | -1.78% | Upgrade
|
| Free Cash Flow Margin | -2.42% | -0.15% | -1.52% | -3.63% | 1.96% | Upgrade
|
| EBITDA | 33,312 | -7,253 | 18,655 | -4,446 | -1,247 | Upgrade
|
| EBITDA Margin | 5.87% | -1.03% | 2.57% | -0.62% | -0.18% | Upgrade
|
| D&A For EBITDA | 12,317 | 11,297 | 9,767 | 8,886 | 9,133 | Upgrade
|
| EBIT | 20,995 | -18,550 | 8,888 | -13,332 | -10,380 | Upgrade
|
| EBIT Margin | 3.70% | -2.63% | 1.22% | -1.85% | -1.48% | Upgrade
|
| Effective Tax Rate | 8.44% | - | - | - | - | Upgrade
|
| Advertising Expenses | 9,669 | 9,884 | 9,309 | 11,786 | 14,512 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.